Shutdown delays review of Aimmune peanut allergy therapy

Aimmune Therapeutics Inc. (NASDAQ:AIMT) said FDA notified the company it will not review a BLA for peanut allergy candidate AR101 until the government shutdown has ended. The company disclosed the news in an SEC filing on Jan. 14...